(3R,4S)-4-(2,4,5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: synthesis, in vitro, in vivo, and X-ray crystallographic characterization.
Wright, S.W., Ammirati, M.J., Andrews, K.M., Brodeur, A.M., Danley, D.E., Doran, S.D., Lillquist, J.S., Liu, S., McClure, L.D., McPherson, R.K., Olson, T.V., Orena, S.J., Parker, J.C., Rocke, B.N., Soeller, W.C., Soglia, C.B., Treadway, J.L., Vanvolkenburg, M.A., Zhao, Z., Cox, E.D.(2007) Bioorg Med Chem Lett 17: 5638-5642
- PubMed: 17822893
- DOI: https://doi.org/10.1016/j.bmcl.2007.07.081
- Primary Citation of Related Structures:
2QJR - PubMed Abstract:
A series of pyrrolidine based inhibitors of dipeptidyl peptidase IV were developed from a high throughput screening hit for the treatment of type 2 diabetes. Potency, selectivity, and pharmacokinetic properties were optimized resulting in the identification of a pre-clinical candidate for further profiling.
Organizational Affiliation:
Pfizer Global Research and Development, Cardiovascular and Metabolic Diseases, MS 8220-3141, Eastern Point Road, Groton, CT 06340, USA.